carboplatin + eftilagimod alpha + pembrolizumab + pemetrexed

A combination therapy consisting of carboplatin (a platinum-based chemotherapy), eftilagimod alpha (a soluble LAG-3 protein that acts as an MHC class II agonist), pembrolizumab (an anti-PD-1 immunotherapy), and pemetrexed (an antifolate chemotherapy). This combination targets cancer through multiple mechanisms: the chemotherapy components (carboplatin and pemetrexed) directly destroy rapidly dividing cancer cells, while the immunotherapy components (pembrolizumab and eftilagimod alpha) enhance the immune system's ability to recognize and attack cancer cells. Eftilagimod alpha specifically activates antigen-presenting cells and T-cells, potentially helping overcome resistance to PD-1/PD-L1 inhibitors like pembrolizumab.